[Quality control of platelet concentrates. Functional assessment of stored platelets in vitro]
- PMID: 8304580
[Quality control of platelet concentrates. Functional assessment of stored platelets in vitro]
Abstract
Platelet concentrates transfused for correction of thrombocytopenia or reduced platelet function do not consistently improve primary haemostasis in the recipient. Insufficient therapeutic effects may be caused by impaired donor platelet function and by unfavourable donation and storage conditions, as well as by immunological interactions with the recipient blood. The present study was designed to investigate whether the effect of platelet transfusion on recipient platelet function can be predicted by in vitro methods. METHODS. Blood samples were taken from 12 thrombocytopenic patients before (20 ml, P0) and after (10 ml, P(vivo)) transfusion of one unit of platelets previously stored for 24-120 h in acid citrate dextrose. An additional sample was taken from the platelet concentrate (TK) immediately before transfusion. P0 was divided into two specimens and TK platelets were added to one of them (P(vitro) in order to obtain a platelet count similar to that in P(vivo). Bleeding time (BT) and bleeding volume (BV) of the samples P0, P(vivo) and P(vitro) were measured using the method of Kratzer and Born (Fig. 2); mean values were calculated for each sample from six measurements. Aggregability of TK platelets was determined in addition by aggregometry. In contrast to previous studies, physiological Ca2+ concentrations were restored and secondary haemostasis was inhibited by low-molecular-weight heparin (Fragmin P, Pfrimmer Kabi GmbH und Co. KG, Erlangen) in the platelet-rich plasma used for aggregometry. RESULTS. Platelet counts increased in all patients after transfusion (P(vivo) vs P0, Table 1) and were nearly identical in P(vitro) and P(vivo) (r = 0.94, P < 0.001; Fig. 3). Parameters of primary haemostasis were significantly improved by addition of platelets to P0 in vitro (BT P < 0.05, BV P < 0.01) as well as by platelet transfusion (BT P < 0.05, BV P < 0.01). Direct comparison of P(vitro) and P(vivo) yielded a very close correlation of BT (r = 0.88, P < 0.001) and BV (r = 0.89, P < 0.01) in both samples. Although aggregometry revealed decreasing platelet function with increased storage time, aggregability was considerably higher compared to previous studies of platelet concentrates stored for 2-5 days. CONCLUSION. A new technique has been developed which allows reliable prediction of the effect of platelet concentrates on primary haemostasis of the recipient by in vitro measurement of bleeding time and bleeding volume prior to transfusion using the method of Kratzer and Born.
Similar articles
-
Suitability of measurement of swirling as a marker of platelet shape change in concentrates stored for transfusion.Platelets. 2006 Sep;17(6):393-6. doi: 10.1080/09537100600757695. Platelets. 2006. PMID: 16973500
-
Correlation between the extent of platelet activation in platelet concentrates and in vitro and in vivo parameters.Vox Sang. 2004 Nov;87(4):257-63. doi: 10.1111/j.1423-0410.2004.00573.x. Vox Sang. 2004. PMID: 15585021 Clinical Trial.
-
A method for the quantitative assessment of platelet-induced clot retraction and clot strength in fresh and stored platelets.Vox Sang. 1998;75(4):270-7. Vox Sang. 1998. PMID: 9873262 Clinical Trial.
-
Volume-reduced platelet concentrates.Curr Hematol Rep. 2006 Mar;5(1):82-8. Curr Hematol Rep. 2006. PMID: 16537051 Review.
-
Contribution of perfusion techniques to the evaluation of the hemostatic effectiveness of platelet concentrates.Blood Cells. 1992;18(3):403-15; discussion 416-20. Blood Cells. 1992. PMID: 1286195 Review.
Publication types
MeSH terms
LinkOut - more resources
Miscellaneous